Marine Source‐derived Anti‐HIV Therapeutics

Mirani, Amit; Shah, Tanvi K.; Patravale, Vandana

doi:10.1002/9781119143802.ch121

Cited by 2 publications

(3 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Rubromycins are characterised by a challenging molecular structure consisting of a naphthazarin moiety linked to an isocoumarin ring by a bis-benzannulated 5, 6-spiroketal system [ 26 , 27 ]. It has broad biological activities including antibacterial and anticarcinogenic activity [ 26 , 28 , 29 , 30 ] and activity against human telomerase-16 [ 31 ] and HIV-1 reverse transcriptase [ 32 ]. Studies show that there is a direct link between cancer and human telomerase, and that the spiroketane moiety of rubromycin is important in inhibiting it [ 7 , 33 ].…”

Section: Introductionmentioning

confidence: 99%

Streptomyces iakyrus TA 36 as First-Reported Source of Quinone Antibiotic γ–Rubromycin

et al. 2023

View full text Add to dashboard Cite

A wide range of bioactive compounds with potential medical applications are produced by members of the genus Streptomyces. A new actinomycete producer of the antibiotic γ-rubromycin, designated TA 36, was isolated from an alpine soil sample collected in Peru (Machu Picchu). Morphological, physiological and biochemical characteristics of the strain, together with data obtained via phylogenetic analysis and MALDI-TOF MS, were used for the correct identification of the isolate. The isolate TA 36 showed morphological characteristics that were consistent with its classification within the genus Streptomyces. Phylogenetic analysis based on 16S rRNA gene sequences showed that the TA 36 strain was most similar to S. iakyrus and S. violaceochromogenes with 99% similarity. Phylogenetic analysis together with the profile of whole cell proteins indicated that the strain tested could be identified as S. iakyrus TA 36. The crude extract Ext.5333.TA 36 showed various effects against the tested organisms with strong antimicrobial activity in the growth of Staphylococcus aureus (Newman) (MIC value of 0.00195 µg/µL). HPLC fractionation and LC/MS analysis of the crude extract led to the identification of the quinone antibiotic γ-rubromycin, a promising antitumour and antibacterial antibiotic. To the best of our knowledge, there is currently no report on the production of γ-rubromycin by S. iakyrus. Therefore, this study suggests S. iakyrus TA 36 as the first-reported source of this unique bioactive secondary metabolite.

show abstract

Section: Introductionmentioning

confidence: 99%

Streptomyces iakyrus TA 36 as First-Reported Source of Quinone Antibiotic γ–Rubromycin

et al. 2023

View full text Add to dashboard Cite

show abstract

“…After the completion of the translation process in the cytoplasm, new virus infectious particles (virions) are formed, which also undergo trimming inside the capsid and may infect the targeted cells, responding as a mature virus [10] as depicted in Figure 1. Various research studies highlight the potential of MBAPs against the replication of HIV [11][12][13][14]. The current review considers the existing knowledge regarding the activity of MBAPs against HIV by exploring databases such as PubMed, ScienceDirect, SciFindern, and Embase, and using keyword combinations including bioactive peptides, marine bioactive peptides, anti-HIV, marine organisms, and antiretroviral agents.…”

Section: Introductionmentioning

confidence: 99%

“…Various research studies highlight the potential of MBAPs against the replication of HIV [ 11 , 12 , 13 , 14 ]. The current review considers the existing knowledge regarding the activity of MBAPs against HIV by exploring databases such as PubMed, ScienceDirect, SciFinder-n, and Embase, and using keyword combinations including bioactive peptides, marine bioactive peptides, anti-HIV, marine organisms, and antiretroviral agents.…”

Section: Introductionmentioning

confidence: 99%

Therapeutic Potential of Marine Bioactive Peptides against Human Immunodeficiency Virus: Recent Evidence, Challenges, and Future Trends

et al. 2022

View full text Add to dashboard Cite

Acquired immunodeficiency syndrome (AIDS) is a chronic and potentially fatal ailment caused by the human immunodeficiency virus (HIV) and remains a major health problem worldwide. In recent years, the research focus has shifted to a greater emphasis on complementing treatment regimens involving conventional antiretroviral (ARV) drug therapies with novel lead structures isolated from various marine organisms that have the potential to be utilized as therapeutics for the management of HIV-AIDS. The present review summarizes the recent developments regarding bioactive peptides sourced from various marine organisms. This includes a discussion encompassing the potential of these novel marine bioactive peptides with regard to antiretroviral activities against HIV, preparation, purification, and processing techniques, in addition to insight into the future trends with an emphasis on the potential of exploration and evaluation of novel peptides to be developed into effective antiretroviral drugs.

show abstract

Marine Source‐derived Anti‐HIV Therapeutics

Cited by 2 publications

References 74 publications

Streptomyces iakyrus TA 36 as First-Reported Source of Quinone Antibiotic γ–Rubromycin

Streptomyces iakyrus TA 36 as First-Reported Source of Quinone Antibiotic γ–Rubromycin

Therapeutic Potential of Marine Bioactive Peptides against Human Immunodeficiency Virus: Recent Evidence, Challenges, and Future Trends

Contact Info

Product

Resources

About